Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer › Research Explorer

DOI

https://doi.org/10.1186/s12885-022-09436-0
Final published version

Sanne ten Hoorn
Cynthia Waasdorp
Martijn G. H. van Oijen
Helene Damhofer
Anne Trinh
Lan Zhao
Lisanne J. H. Smits
Sanne Bootsma
Gabi W. van Pelt
Wilma E. Mesker
Linda Mol
Kaitlyn K. H. Goey
Miriam Koopman
Jan Paul Medema
Jurriaan B. Tuynman
Inti Zlobec
Cornelis J. A. Punt
Louis Vermeulen
Maarten F. Bijlsma

Original language	English
Article number	394
Journal	BMC cancer
Volume	22
Issue number	1
DOIs	https://doi.org/10.1186/s12885-022-09436-0
Publication status	Published - 1 Dec 2022

Research areas

ADAM12, Colorectal cancer, Prognostic marker, Stroma

ID: 23140746